Fig. 2.

In vitro perturbation experiments: results. a Clinically relevant drugs (abbreviations see caption of Fig. 1) focus on interfering with AR and PI3K-AKT-mTOR pathways. Docetaxel was chosen due to its widespread use in treating prostate cancer. b Protein abundances were quantified by mass spectrometry in SRM mode, log2 transformed and relative protein ratios (treated/untreated) calculated. Unsupervised clustering of these protein values per condition across the entire perturbation matrix resulted in clusters of proteins largely upregulated and proteins largely downregulated as short-term response to drug treatment. Protein names are standard gene names